STERIS plc Reports Q1 FY2027 Results; Announces U.S. Chemistries Consolidation

What Happened

• On August 5, 2026 STERIS plc (STE) filed an 8‑K and issued a press release (Exhibit 99.1) reporting financial results for the quarter ended June 30, 2026 (fiscal Q1 FY2027).
• The company also announced a targeted Consolidation Plan to move formulated-chemistries manufacturing and distribution to a new Center of Excellence in North Carolina, and to close chemistry manufacturing/distribution facilities in St. Louis, Missouri and Plymouth, Minnesota.

Key Details

• Press release filed Aug 5, 2026 for quarter ended June 30, 2026 (Exhibit 99.1).
• Expected total pre-tax restructuring charges: approximately $55 million to $70 million.
  • Cash expenditures: ~$40M–$50M (associate retention, severance, benefits, transition and facility exit costs).
  • Non-cash charges: ~$15M–$20M (primarily accelerated depreciation).
• Charges to be incurred over time with completion anticipated in fiscal 2030; these charges will be excluded from the company’s adjusted earnings measurements.

Why It Matters

• The consolidation and associated $55–$70M charge will affect STERIS’s near-term GAAP results and cash flow (mainly via the ~$40–50M in cash outlays), while management expects the move to expand capacity, accelerate innovation and optimize the U.S. chemistries manufacturing/distribution network over the longer term.
• Investors should watch upcoming quarterly disclosures for the detailed financial results in the attached press release and for further updates on restructuring timing, cash expenditures, and any operational or workforce impacts stemming from the facility closures.